Pharmaceuticals, Biotechnology and Life Sciences
Mainz Biomed, a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Rainer Metzger to its Strategic Advisory Board.
Active Biotech, a Sweden- based biotechnology company, has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in treatment of myelofibrosis (MF).
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility.
AiCuris Anti-infective Cures AG (AiCuris), a company focused to the discovery and development of drugs against infectious diseases, and Hybridize…
The startup company Novel Concepts Medical has announced major breakthrough in its research of COVID-19. Its novel plant-based treatment has…
The next phase of the Company’s strategy is to expand the Group’s capabilities by reinvesting proceeds from the recent sale of shares held in SkinBioTherapeutics plc, which generated approximately £2 million. These funds have provided growth capital to broaden and expand the Group’s sales and marketing team, accelerate new product development, increase marketing spend and explore direct to consumer channels in strategic markets. These funds also allow the Company to invest in acquiring new technologies to create a future pipeline of products. This supplements existing plans for expanding product ranges into sports nutrition (LeanBiome™) and healthy ageing (WellBiome®), extending SlimBiome®, OptiBiome®, and LPLDL® product lines and territories, increasing the number of larger partners, and growing gross profit by moving up the value chain to sell a greater portion of finalised products than functional ingredients.
Biosimilars have the potential to broaden patient access to effective and more affordable treatments and generate healthcare savingsCAMBRIDGE, Mass and…
Medix Biochemica has acquired 100 percent of the shares of myPOLS Biotec GmbH. As a result of the acquisition, Medix…
Sanofi today unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in…
The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced top-line data from a Phase 1b/2 clinical trial evaluating alvelestat, a novel, orally active Neutrophil Elastase (NE) inhibitor in hospitalized COVID-19 Respiratory Disease patients.